Jacobio Pharma grants Allist China rights to two assets

Jacobio Pharma has entered into an agreement with Shanghai Allist Pharmaceuticals, granting them the rights to two key assets, glecirasib and JAB-3312, within China, including Hong Kong, Macau, and Taiwan. Glecirasib is a Kirsten rat sarcoma glycine 12 to cysteine (KRAS G12C) inhibitor, while JAB-3312 is an Src homology-2 domain-containing protein tyrosine phosphatase 2 (SHP2) inhibitor.

Under this deal, Jacobio will receive an initial payment of 150 million yuan and an additional 50 million yuan to cover research and development expenses and other related costs, totaling 200 million yuan (approximately $28 million). Moreover, the agreement outlines potential milestone payments amounting to 700 million yuan, contingent on achieving specific development, regulatory, and commercial objectives.

Jacobio stands to earn tiered royalty payments based on the net sales revenue of these products, with the possibility of royalty payments for JAB-3312 reaching up to 20%. Allist will be responsible for the commercialisation of these assets within China, as well as bearing the costs of their further clinical development.

Glecirasib has already shown promise, particularly in the treatment of second-line non-small cell lung cancer (NSCLC) with KRAS G12C mutations. In December 2022, it was granted breakthrough therapy designation in China. By May 2024, it had received priority review for its new drug application as a monotherapy for second-line NSCLC.

Clinical trials have shown encouraging results for glecirasib. Data from a Phase II study in April 2024 demonstrated a confirmed objective response rate of 47.9% among second-line NSCLC patients, with a disease control rate of 86.3%. These patients had a median progression-free survival of 8.2 months and a median overall survival of 13.6 months. Recently, the first subject was dosed in a Phase III clinical trial comparing the combination of glecirasib and JAB-3312 against the current standard care.

Beyond NSCLC, glecirasib is also being tested in crucial studies for second-line or higher pancreatic cancer and in combination with cetuximab for colorectal cancer.

Jacobio Pharma’s chairman and CEO, Dr. Wang Yinxiang, expressed optimism about the partnership with Allist, noting their strong commercial capabilities in the field of lung cancer. He emphasized that the new drug application for glecirasib’s first indication is lung cancer, highlighting the complementary strengths of both companies. Dr. Wang believes that this collaboration will not only advance clinical outcomes but also bring significant commercial value.

He further commented on JAB-3312, pointing out that it is the first SHP2 inhibitor to enter a registrational trial globally. The expectation is that JAB-3312, when combined with glecirasib, could become a first-line therapy, showcasing Allist’s strategic vision for future treatment pipelines.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!